Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.
2.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

3.

Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Tandon N, Ali MK, Narayan KM.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Review.

PMID:
22217193
4.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
5.

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.

PMID:
7587846
6.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
7.

[New treatment strategies for type-2 diabetes?].

Halimi S.

Presse Med. 2005 Oct 22;34(18):1287-92. Review. French.

PMID:
16269991
9.

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.

Huang ES, Meigs JB, Singer DE.

Am J Med. 2001 Dec 1;111(8):633-42.

PMID:
11755507
10.

Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.

Steinmetz A.

Diabetes Metab Res Rev. 2008 May-Jun;24(4):286-93. doi: 10.1002/dmrr.806. Review.

PMID:
18273835
11.
12.

Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.

Verg├Ęs B.

Curr Opin Lipidol. 2006 Dec;17(6):653-8. Review.

PMID:
17095910
13.

Effect of baseline glycemic level on long-term cardiovascular outcomes after coronary revascularization therapy in patients with type 2 diabetes mellitus treated with hypoglycemic agents.

Ehara N, Morimoto T, Furukawa Y, Shizuta S, Taniguchi R, Nakagawa Y, Hoshino K, Saito N, Doi T, Haruna Y, Ozasa N, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T.

Am J Cardiol. 2010 Apr 1;105(7):960-6. doi: 10.1016/j.amjcard.2009.11.024. Epub 2010 Feb 13.

PMID:
20346313
14.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
15.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial--clinical implications.

Ismail-Beigi F.

Clin Chem. 2011 Feb;57(2):261-3. doi: 10.1373/clinchem.2010.148288. Epub 2010 Oct 25. No abstract available.

17.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
18.
19.

The HOPE Study (Heart Outcomes Prevention Evaluation).

Sleight P.

J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):18-20. Review.

PMID:
11967789
20.

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N.

Nutr Metab Cardiovasc Dis. 2009 Nov;19(9):604-12. doi: 10.1016/j.numecd.2009.03.021. Epub 2009 May 8.

PMID:
19427768
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk